← Azimuth Daily
Capturing data…
Capturing data…
MON, 28 SEPT · 76 ITEMS
"Single-dose CRISPR therapy cut LDL cholesterol by half for a year in patients with hard-to-treat lipid disorders" — Science Daily (all) · Science & Medicine
This reports results from a of a single-dose gene-editing therapy targeting the gene. The treatment, delivered as an infusion, reduced LDL ("bad") cholesterol by roughly half in patients with difficult-to-manage high cholesterol (such as familial hypercholesterolemia), and that effect persisted for at least a year, suggesting a potential "one-and-done" solution for a condition that normally requires daily medication.
The claim is well-supported by consistent reporting from multiple reputable outlets (New York Times, NHS trusts) that are closely summarizing the primary source—the trial's data release from the biotech company or academic center running the study. The specific effect size (~50% LDL reduction) is consistently cited, but it remains a small Phase 1 study, so long-term durability and broader efficacy are still under investigation.
Genuinely new. The trial results were published and broadly reported throughout 2026, with major coverage appearing in mid-to-late 2026 (e.g., NYT, August 2026), and the highlight reflects this current reporting wave.
We covered this exact story in September 2026, reporting that the maintained its cholesterol-lowering effect for at least a year.